Price Alert

CorMedix Inc. (CRMD)

NASDAQ: CRMD · Real-Time Price · USD

13.21

0.11 (0.84%)

At close: Aug 19, 2025, 12:08 PM

0.84% (1D)

Bid	13.18
Market Cap	986.01M
Revenue (ttm)	82.55M
Net Income (ttm)	17.18M
EPS (ttm)	0.78
PE Ratio (ttm)	16.93
Forward PE	5.73
Analyst	Buy

Ask	13.21
Volume	901,115
Avg. Volume (20D)	2,330,508
Open	13.08
Previous Close	13.10
Day's Range	12.89 - 13.32
52-Week Range	4.87 - 17.43
Beta	1.71

About CRMD

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CRMD

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CRMD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

CorMedix Inc. is scheduled to release its earnings on Oct 29, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-16.44%

CorMedix shares are trading lower after the compan... Unlock content with Pro Subscription

1 month ago

-0.07%

CorMedix shares are trading lower after the company announced an $85 million public offering.

News

19 hours ago · zacks.com

Wall Street Analysts Believe CorMedix (CRMD) Could Rally 45.63%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the posit...

5 days ago · zacks.com

Why CorMedix (CRMD) Might be Well Poised for a Surge

CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

1 week ago · seekingalpha.com

CorMedix, Inc. (CRMD) Q2 2025 Earnings Call Transcript

CorMedix, Inc. (NASDAQ:CRMD ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Joseph Todisco - CEO & Director Matthew T. David - Executive VP & CFO Conference Call Part...

1 week ago · wsj.com

CorMedix to Buy Melinta Therapeutics for $300 Million

The buyer said the deal adds six marketed infectious-disease products to its offerings.

1 week ago · zacks.com

CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates

CorMedix (CRMD) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to a loss of $0.25 per share a year ago.

1 week ago · businesswire.com

Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership

PARSIPPANY, N.J.--(BUSINESS WIRE)--Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring its Portfolio Value and Industry Leadership.

1 week ago · zacks.com

CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release

CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · zacks.com

Does CorMedix (CRMD) Have the Potential to Rally 65.64% as Wall Street Analysts Expect?

The mean of analysts' price targets for CorMedix (CRMD) points to a 65.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst...

3 weeks ago · zacks.com

CorMedix (CRMD) Soars 5.1%: Is Further Upside Left in the Stock?

CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

1 month ago · zacks.com

Can CorMedix (CRMD) Keep the Earnings Surprise Streak Alive?

CorMedix (CRMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Load More News